Giacomo Deferrari

List of Publications by Year
in descending order

88 papers	4,401 citations	101543 36 h-index	106344 65 g-index
89 all docs	89 docs citations	89 times ranked	4879 citing authors

#	Article	IF	Citations
1	Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. Journal of the American Society of Nephrology: JASN, 2005, 16, 3027-3037.	6.1	341
2	Nephrin Expression Is Reduced in Human Diabetic Nephropathy. Diabetes, 2003, 52, 1023-1030.	0.6	319
3	Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. American Journal of Kidney Diseases, 2005, 45, 281-287.	1.9	317
4	Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2008, 295, F1563-F1573.	2.7	219
5	Prevalence and Clinical Correlates of Microalbuminuria in Essential Hypertension. Hypertension, 1997, 30, 1135-1143.	2.7	165
6	Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension, 2005, 45, 991-996.	2.7	145
7	Increased Ambulatory Arterial Stiffness Index Is Associated With Target Organ Damage in Primary Hypertension. Hypertension, 2006, 48, 397-403.	2.7	135
8	Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney International, 1994, 45, 1432-1439.	5.2	126
9	Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes. Diabetes, 2009, 58, 2109-2118.	0.6	110
10	Testosterone promotes apoptotic damage in human renal tubular cells. Kidney International, 2004, 65, 1252-1261.	5.2	104
11	Importance of Blood Pressure Control in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, S98-S103.	6.1	104
12	Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Journal of Hypertension, 1999, 17, 993-1000.	0.5	97
13	Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells. Journal of Investigative Medicine, 2002, 50, 443-451.	1.6	87
14	Oxidative Stress Mediates Apoptotic Changes Induced by Hyperglycemia in Human Tubular Kidney Cells. Journal of the American Society of Nephrology: JASN, 2004, 15, 85S-87.	6.1	77
15	Ambulatory arterial stiffness index and renal abnormalities in primary hypertension. Journal of Hypertension, 2006, 24, 2033-2038.	0.5	77
16	Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension. Hypertension, 2003, 42, 14-18.	2.7	69
17	Renal Metabolism of C-Peptide in Man*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 494-498.	3.6	67
18	Serum Uric Acid Levels Predict New-Onset Type 2 Diabetes in Hospitalized Patients With Primary Hypertension: The MAGIC Study. Diabetes Care, 2011, 34, 126-128.	8.6	65

#	Article	IF	Citations
19	Changes in Renal Resistive Index and Urinary Albumin Excretion in Hypertensive Patients under Long-Term Treatment with Lisinopril or Nifedipine GITS. Nephron, 2002, 90, 169-173.	1.8	63
20	Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney International, 2000, 57, 561-569.	5.2	62
21	Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S169-S172.	6.1	62
22	Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach.. Journal of Hypertension, 2002, 20, 1315-1321.	0.5	61
23	CKD Awareness and Blood Pressure Control in the Primary Care Hypertensive Population. American Journal of Kidney Diseases, 2011, 57, 71-77.	1.9	58
24	Mild Renal Dysfunction and Renal Vascular Resistance in Primary Hypertension. American Journal of Hypertension, 2005, 18, 966-971.	2.0	56
25	Volatile Anesthetics versus Propofol for Cardiac Surgery with Cardiopulmonary Bypass. Anesthesiology, 2020, 132, 1429-1446.	2.5	54
26	RAGEâ€•and TGFâ€•Î² receptorâ€mediated signals converge on STAT5 and p21 waf to control cellâ€cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB Journal, 2004, 18, 1249-1251.	0.5	52
27	Brain metabolism of amino acids and ammonia in patients with chronic renal insufficiency. Kidney International, 1981, 20, 505-510.	5.2	50
28	Microalbuminuria Is a Predictor of Chronic Renal Insufficiency in Patients without Diabetes and with Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1099-1106.	4.5	50
29	Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus. Journal of the American Society of Nephrology: JASN, 2002, 13, S224-S229.	6.1	47
30	Mild Hyperuricemia and Subclinical Renal Damage in Untreated Primary Hypertension. American Journal of Hypertension, 2007, 20, 1276-1282.	2.0	46
31	Acute Effects of Peritoneal Dialysis with Dialysates Containing Dextrose or Dextrose and Amino Acids on Muscle Protein Turnover in Patients with Chronic Renal Failure. Journal of the American Society of Nephrology: JASN, 2001, 12, 557-567.	6.1	42
32	Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney International, 2004, 66, S99-S101.	5.2	40
33	Androgen-mediated apoptosis of kidney tubule cells: Role of c-Jun amino terminal kinase. Biochemical and Biophysical Research Communications, 2009, 387, 531-536.	2.1	40
34	Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. Journal of Hypertension, 2010, 28, 156-162.	0.5	40
35	Renal ammoniagenesis in humans with chronic potassium depletion. Kidney International, 1991, 40, 772-778.	5.2	39
36	Inter-organ Leptin Exchange in Humans. Biochemical and Biophysical Research Communications, 1998, 247, 504-509.	2.1	39

#	Article	IF	Citations
37	Leg Metabolism of Amino Acids and Ammonia in Patients with Chronic Renal Failure. Clinical Science, 1985, 69, 143-151.	4.3	36
38	Kidney Protein Dynamics and Ammoniagenesis in Humans with Chronic Metabolic Acidosis. Journal of the American Society of Nephrology: JASN, 2004, 15, 1606-1615.	6.1	36
39	Optimizing global risk evaluation in primary hypertension. Journal of Hypertension, 2004, 22, 907-913.	0.5	36
40	Sex differences in hypertension-related renal and cardiovascular diseases in Italy. Journal of Hypertension, 2012, 30, 2378-2386.	0.5	36
41	Interorgan exchange of aminothiols in humans. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E757-E763.	3.5	35
42	Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. Journal of Nephrology, 2002, 15, 519-24.	2.0	34
43	Coronary Flow Reserve Is Impaired in Hypertensive Patients With Subclinical Renal Damage. American Journal of Hypertension, 2009, 22, 191-196.	2.0	32
44	Remote ischaemic preconditioning for renal and cardiac protection in adult patients undergoing cardiac surgery with cardiopulmonary bypass: systematic review and meta-analysis of randomized controlled trials. Nephrology Dialysis Transplantation, 2018, 33, 813-824.	0.7	32
45	Renal dysfunction in cardiovascular diseases and its consequences. Journal of Nephrology, 2021, 34, 137-153.	2.0	32
46	Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation. Journal of the American Society of Nephrology: JASN, 2005, 16, S48-S52.	6.1	30
47	Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. Journal of Hypertension, 2010, 28, 848-855.	0.5	30
48	Global risk stratification in primary hypertension: the role of the kidney. Journal of Hypertension, 2008, 26, 427-432.	0.5	28
49	Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2009, 27, 410-417.	0.5	28
50	5,10-methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. American Journal of Hypertension, 2001, 14, 371-376.	2.0	27
51	Microalbuminuria, Blood Pressure Load, and Systemic Vascular Permeability in Primary Hypertension. American Journal of Hypertension, 2006, 19, 1183-1189.	2.0	25
52	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2010, 28, 251-258.	0.5	25
53	Renal and cardiac abnormalities in primary hypertension. Journal of Hypertension, 2009, 27, 1064-1073.	0.5	22
54	Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment. Journal of the American Society of Nephrology: JASN, 2004, 15, 6S-11.	6.1	21

#	Article	IF	Citations
55	Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. Nephrology Dialysis Transplantation, 2009, 24, 1528-1533.	0.7	21
56	Metabolic Syndrome and Cardiovascular Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, S120-S122.	6.1	20
57	Treatment of diabetic nephropathy in its early stages. Diabetes/Metabolism Research and Reviews, 2003, 19, 101-114.	4.0	19
58	Role of Microalbuminuria in the Assessment of Cardiovascular Risk in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2005, 16, S39-S41.	6.1	19
59	Evaluation of Subclinical Organ Damage for Risk Assessment and Treatment in the Hypertensive Patient: Role of Microalbuminuria. Journal of the American Society of Nephrology: JASN, 2006, 17, S112-S114.	6.1	19
60	Treatment of Diabetic Nephropathy in its Early Stages. , 1997, 13, 51-61.		17
61	Impact of Target Organ Damage Assessment in the Evaluation of Global Risk in Patients with Essential Hypertension: Figure 1.. Journal of the American Society of Nephrology: JASN, 2005, 16, S89-S91.	6.1	16
62	Microalbuminuria and Cardiovascular Risk Assessment in Primary Hypertension: Should Threshold Levels Be Revised?. American Journal of Hypertension, 2006, 19, 728-734.	2.0	15
63	Metabolic syndrome and chronic kidney disease in high-risk Italian hypertensive patients: the I-DEMAND study. Journal of Nephrology, 2012, 25, 63-74.	2.0	15
64	Apoptosis Induced by Serum Withdrawal in Human Mesangial Cells. Nephron Experimental Nephrology, 2001, 9, 366-371.	2.2	14
65	Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. Journal of Hypertension, 2008, 26, 345-350.	0.5	13
66	Left-Ventricular Hypertrophy and Renal Outcome in Hypertensive Patients In Primary-Care. American Journal of Hypertension, 2013, 26, 700-707.	2.0	13
67	TT virus infection in haemodialysis patients. Nephrology Dialysis Transplantation, 2000, 15, 1823-1826.	0.7	11
68	Vascular Permeability, Blood Pressure, and Organ Damage in Primary Hypertension. Hypertension Research, 2008, 31, 873-879.	2.7	11
69	Mechanisms of renal ammonia production and protein turnover. Metabolic Brain Disease, 2009, 24, 159-167.	2.9	11
70	Amino Acid Imbalance in Patients with Chronic Renal Failure. Contributions To Nephrology, 1989, 75, 185-193.	1.1	10
71	Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions. Free Radical Research, 2006, 40, 207-212.	3.3	10
72	Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. Clinica Chimica Acta, 2011, 412, 1951-1956.	1.1	10

#	Article	IF	Citations
73	Renal Metabolism of C-Peptide in Patients with Early Insulin-Dependent Diabetes mellitus. Nephron, 1996, 72, 395-401.	1.8	9
74	Fibroblast Na+â€“Li+ countertransport rate is elevated in essential hypertension. Journal of Hypertension, 2001, 19, 1263-1269.	0.5	9
75	High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application. Journal of Hypertension, 2014, 32, 1245-1254.	0.5	9
76	C-reactive protein and target organ damage in untreated patients with primary hypertension. Journal of the American Society of Hypertension, 2007, 1, 407-413.	2.3	8
77	The role of kidney dysfunction in COVID-19 and the influence of age. Scientific Reports, 2022, 12, .	3.3	8
78	Chronic Kidney Disease in the Hypertensive Patient. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 31-36.	2.2	6
79	Muscle Amino Acid and Protein Metabolism in Chronic Renal Failure. Contributions To Nephrology, 1992, 98, 1-10.	1.1	4
80	Predicting cardiovascular risk using creatinine clearance and an artificial neural network in primary hypertension. Journal of Hypertension, 2006, 24, 1281-1286.	0.5	4
81	Abnormalities in Amino Acid Metabolism in Patients with Chronic Renal Failure. Contributions To Nephrology, 1987, 55, 1-10.	1.1	1
82	Abnormalities in Amino Acid Metabolism in Chronic Renal Failure. Contributions To Nephrology, 1990, 81, 169-180.	1.1	1
83	Medicine in Italy. Lancet, The, 1996, 348, 679.	13.7	1
84	Response to â€˜Renal microvascular and tubular injuries in type II diabetic nephropathyâ€™. Kidney International, 2008, 74, 390-391.	5.2	1
85	Cardiovascular Risk in Hypertensive Patients with Renal Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 13-20.	2.2	1
86	Renal metabolism of amino acids in early insulin-dependent diabetes mellitus. The Journal of Diabetic Complications, 1991, 5, 101-103.	0.2	0
87	Pulse pressure (PP) and early signs of target organ damage (TOD) in essential hypertension (EH). American Journal of Hypertension, 2001, 14, A161.	2.0	0
88	Cardionephrology, an emerging discipline: highlights of the Sixth Genoa Meeting on Hypertension, Diabetes and Renal Disease. Therapy: Open Access in Clinical Medicine, 2007, 4, 487-489.	0.2	0